Aims To test the hypothesis that inhibition of cytochrome P450 2D6 (CYP2D6) by quinidine increases the antitussive effect of dextromethorphan (DEX) in an induced cough model. Methods Twenty-two healthy extensive metaboliser phenotypes for CYP2D6 were studied according to a double-blind, randomised cross-over design after administration of : (1) Placebo antitussive preceded at 1 h by placebo inhibitor; (2) 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30); (3) 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60); (4) 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30). Cough frequency following inhalation of 10% citric acid was measured at baseline and at intervals up to 12 h. Plasma concentrations of DEX and its metabolites were measured up to 96 h by h.p.l.c. Results Inhibition of CYP2D6 by quinidine caused a significant increase in the mean ratio of DEX to dextrorphan (DEX5DOR) plasma AUC(96) (0.04 vs 1.81, P<0.001). The mean (±s.d.) decrements in cough frequency below baseline over 12 h (AUEC) were: 8% (11), 17% (14.5), 25% (16.2) and 25% (16.9) for placebo, DEX30, DEX60 and QDEX30 treatments, respectively. Statistically significant differences in antitussive effect were detected for the contrasts between DEX60/placebo ( P<0.001; 95% CI of difference +80, +327) and QDEX30/placebo ( P<0.001, +88, +336), but not for DEX30/placebo, DEX30/DEX60 or DEX30/QDEX30 ( P=0.071, −7, +241; P=0.254, −37, +211; P=0.187, −29, +219, respectively). Conclusions A significant antitussive effect was demonstrated after 60 mg dextromethorphan and 30 mg dextromethorphan preceded by 50 mg quinidine using an induced cough model. However, although the study was powered to detect a 10% difference in cough response, the observed differences for other contrasts were less than 10%, such that it was possible only to imply a dose effect (30 vs 60 mg ) in the antitussive activity of DEX and enhancement of this effect by CYP2D6 inhibition.
tion [8] . N-demethylation to 3-methoxymorphinan also Introduction occurs, largely by CYP3A4 but with contributions from CYPs 2C9 and 2C19 [9] [10] [11] [12] . Both dextrorphan Dextromethorphan, a codeine analogue devoid of opiate side-effects, is widely available over-the-counter as a and 3-methoxymorphinan are further metabolized to 3-hydroxymorphinan, by CYPs 3A4 and 2D6, respectcough suppressant. Its efficacy has been confirmed in both clinical cough [1] [2] [3] [4] [5] and in experimental cough ively [13] . It is well established that the overall disposition of dextromethorphan is highly dependent upon CYP2D6 challenge studies [6, 7] . Metabolism of dextromethorphan is largely by CYP2D6-mediated O-demethylation to activity, which varies widely due to genetic polymorphism, and which can be inhibited selectively and dextrorphan, which then undergoes glucuronide formasignificantly by a small dose of quinidine [14] [15] [16] .
(extensive metabolisers (EM), genetically poor metab-07.30 h. The treatments were: (1) dextromethorphan placebo, preceded at 1 h by quinidine placebo; (2) olisers (PM), and PM phenocopies produced by coadministration of quinidine). However, the study was dextromethorphan 30 mg (DEX30), preceded at 1 h by quinidine placebo; (3) dextromethorphan 60 mg inconclusive because of insufficient statistical power. The volunteers were not screened for their ability to respond (DEX60), preceded at 1 h by quinidine placebo; (4) dextromethorphan 30 mg, preceded at 1 h by quinidine to the tussive challenge with capsaicin, and the sensitivity of the method was not validated by assessing a dosesulphate 50 mg (QDEX30). The cough challenge was performed at t=−1 h response relationship. In the present study, we have compared the antitussive effect (citric acid challenge) of (immediately before giving placebo inhibitor or active quinidine), t=0 h (immediately before dosing with active dextromethorphan at two dose levels (30 and 60 mg ) and after inhibition of CYP2D6 by coadministration of or placebo dextromethorphan) and at 1, 2, 4, 6, 8, 10 and 12 h after dosing with active or placebo dextromequinidine, using a panel of subjects selected to be sensitive to the cough challenge. The study was powered to detect thorphan. Cough response at baseline was required to be within 40% of that at initial screening. a 10% difference in the efficacy of cough suppression between treatment groups.
Reference data obtained on the screening days showed that the average interoccasion cough response was 10.3 coughs (or 123 coughs over 12 h), with a coefficient of Methods variation (CV) of 13%. Using equation 1 [19] , it was Subjects estimated that the use of 22 subjects in a parallel comparison would provide a power of 90% to detect a Inclusion criteria for the study were EM phenotype for 10% change in cough response (12 coughs over 12 h) CYP2D6 (determined using debrisoquine) [18] , age between treatment groups at a=0.025. 18-45 years, a normal ECG, and FEV 1 >80% predicted value. In addition, the subjects were required to exhibit n>2
(1) a cough response between 7 and 14 coughs when screened on two occasions at least 5 days apart (interoccasion difference <40%; intraoccasion difference <20%).
(where: n=number of subjects; z 2a and z 2b =the stanAt the first screening, a baseline cough response was dardized normal deviate exceeded (in either direction) established. On the second occasion, the cough challenge with probabilities of 2a and 2b, respectively; a and b= was administered at baseline and every hour for 3 h. one side probability of type I and type II errors, Exclusion criteria were smoking, asthma or other signifirespectively; and CV=coefficient of variation). cant respiratory or systemic illness, respiratory tract
The power of the study to detect a similar change infection or acute cough in the previous month.
from multiple comparisons of the four treatments was Twenty-two subjects (12 male, 10 female, mean age estimated to be at least 80% (using the most conservative 24 years), fulfilling the criteria, were recruited to the assumption that a errors are additive). study. They gave written informed consent to the investigation, which was approved by the South Sheffield
Cough challenge Research and Ethics Committee.
A 10% w/v solution of citric acid was prepared by diluting a stock 1 m solution with 0.9% saline, and 3 ml Drugs was placed in a nebulizing chamber. The subjects were Dextromethorphan was given orally as a 60 ml solution required to inhale the nebulized solution over 1 s using containing 30 or 60 mg dextromethorphan hydrobroa breath-activated dosimeter driven by compressed air mide, made from a stock solution (13.5 mg ml −1 ; Boots (Dosimeter MB3, Mefar Elletromedicale). Five inhalations Tusana Cough Syrup). A placebo solution with similar were performed at 1 min intervals over 5 min. The taste was prepared by the Pharmacy Department of the number of coughs was counted following each inhalation Royal Hallamshire Hospital. Quinidine sulphate (50 mg ) and summed for the total 5 min period. and quinidine placebo were administered in the form of identical white capsules.
Blood sampling, drug and metabolite assay
Peripheral venous blood samples (10 ml) were taken Study design though an indwelling Teflon cannula (Wallace Y-Can, Simcare Ltd, W. Sussex UK) at baseline and 0.5, 1, 2, 3, Subjects received four treatments at least 5 days apart according to a randomised (Latin Square) crossover, 4, 8, 12, 24, 48, 72 and 96 h after administration of dextromethorphan. The plasma was separated by double-blind design. Each treatment was commenced at centrifugation and stored at −20°C until assay. lated using the linear trapezoidal rule. Treatments were compared using the General Linear Model (GLM) of Dextromethorphan (DEX), dextrorphan (DOR) (free and conjugated), 3-methoxymorphinan and 3-hydroanova in SPSS v 7.5. Tukey's post hoc test was used for multiple comparisons. Subgroup analysis of phenocopiers xymorphinan (free and conjugated) were measured by the method of Chen et al. [20] . Intra-assay coefficients of was performed similarly. The Wilcoxon signed rank test was used to compare metabolic ratios between treatment variation for the analytes at 2.5 ng ml −1 were between 6 and 13%. Limits of quantification were 0.3 ng ml −1 for groups and the Monte Carlo method to obtain (asymptotic) significance levels and confidence intervals. dextrorphan and 3-hydroxymorphinan, and 0.5 ng ml −1 for dextromethorphan and 3-methoxymorphinan.
The effect of quinidine on cough was examined in each treatment arm using AUEC values from t=−1 h to t=0 h ( pre and post quinidine or placebo inhibitor Statistical analysis administration). Cough suppression was measured as the area under the decrement in cough response below baseline up to 12 h Results (AUEC), calculated using the linear trapezoidal rule. The area under the plasma concentration-time curve up to Summary pharmacokinetic parameters for each treatment are listed in Table 1 . The median DEX5DOR plasma 12 h (AUC(0,12h)) of dextromethorphan was also calcu- analysis of the cough response data for phenocopiers using the alternative antimodes did not alter the results CYP2D6 inhibition also resulted in a corresponding increase in 3-methoxymorphinan and lowering of of the statistical evaluation. 3-hydroxymorphinan concentrations. With regard to the comparison between DEX30 and DEX60, median values Discussion of both the AUC(0,12h) and C max of DEX were increased by only 1.7-fold ( P=0.06; 95% CI of differWe confirm the results of previous studies [14 -16] showing that quinidine markedly inhibits the metabolism ence=+42, −1 and P=0.14; 95% CI of difference= +8, −0.9, respectively) as the dose was raised, while of dextromethorphan, causing a profound increase in the ratio of parent compound to metabolites. However, the t max remained unchanged. The median plasma DOR AUC(12) increased by two-fold ( P<0.001; 95% CI of pharmacodynamic changes accompanying these large pharmacokinetic differences were much smaller. Although difference=+1830, +1122).
Comparisons of the cough response after quinidine a significant antitussive effect of 60 mg dextromethorphan was demonstrated using the citric acid cough challenge ( pre-DEX30) and each administration of placebo inhibitor ( pre-placebo DEX, pre-DEX30 and pre-DEX60) did test, the study failed to show a significant effect of the 30 mg dose relative to placebo or a dose effect between not detect any antitussive effect of quinidine ( P=0.36, 95% CI of difference=−15.7, +3.6; P=0.99, −10.5, 30 and 60 mg. This was despite a statistical power to detect a 10% difference, and the careful selection of +8.8; P=0.9, −7.2, +12.2, respectively).
The time-courses of the mean cough response after subjects who produced a clear, reproducible cough response. The latter screening procedure eliminates each treatment are shown in Figure 1 , and changes in integral (AUEC) values, maximal cough suppression 70-75% of individuals [24] . All of our subjects phenocopied with respect to (E max ) and the median times at which maximum effect occurred are listed in Table 2 . The DEX60 and QDEX30 CYP2D6 after administration of quinidine 50 mg, based treatments produced a maximum response of 50% phan using the citric acid model in guinea pigs.
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Since quinidine markedly inhibits the conversion of 3-hydroxymorphinan does not appear to contribute
